Bristol-Myers Squibb Co.’s (BMY) melanoma drug has received FDA approval for yet another indication – this time as adjuvant therapy for fully resected stage III melanoma. For the nine months ended September 30, 2015, Yervoy had worldwide sales of $861 million, down 9% from the year-ago period. Now, with expanded FDA approvals will Yervoy get its mojo back?